Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuko Yoshio

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
IJU Case Reports|September 9, 2021
A case of adenocarcinoma of the rete testis with durable response to cisplatin-based chemotherapyShunsuke Owa, Takeshi Sasaki, Katsunori Uchida, et al.
Human Genome Variation|July 22, 2022
Succinate dehydrogenase B-deficient renal cell carcinoma with a germline variant in a Japanese patient: a case reportShinichiro Higashi, Takeshi Sasaki, Katsunori Uchida, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 3, 2020
[Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma]Taketomo Nishikawa, Yusuke Sugino, Shunsuke Owa, et al.
Hinyokika Kiyo. Acta Urologica Japonica|January 13, 2021
[A Case of Extragonadal Germ Cell Tumor Treated by Induction Therapy with A Reduced Bep Regimen]Shunsuke Owa, Takeshi Sasaki, Mikiya Ishihara, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 7, 2021
[Presurgical Treatment with Axitinib and Pembrolizumab Reduced Operation Risk by Downsizing the Vena Cava Tumor Thrombus in Clear Cell Renal Cell Carcinoma : A Case Report]Sota Inaba, Takeshi Sasaki, Yuna Hattori, et al.
Cancer Medicine|July 22, 2022
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort studyKatsuhiro Ito, Yuki Kita, Akira Yokomizo, et al.
The Prostate|April 4, 2025
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE StudyTakehiko Okamura, Kouji Izumi, Satoshi Kurokawa, et al.
European Urology Open Science|July 11, 2022
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled TrialKouji Izumi, Takashi Shima, Koji Mita, et al.
The Prostate|September 20, 2024
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCaNobumichi Tanaka, Kouji Izumi, Yasushi Nakai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 20, 2026
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCaSeiji Hoshi, Kouji Izumi, Satoru Meguro, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
IJU Case Reports|September 9, 2021
A case of adenocarcinoma of the rete testis with durable response to cisplatin-based chemotherapyShunsuke Owa, Takeshi Sasaki, Katsunori Uchida, et al.
Human Genome Variation|July 22, 2022
Succinate dehydrogenase B-deficient renal cell carcinoma with a germline variant in a Japanese patient: a case reportShinichiro Higashi, Takeshi Sasaki, Katsunori Uchida, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 3, 2020
[Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma]Taketomo Nishikawa, Yusuke Sugino, Shunsuke Owa, et al.
Hinyokika Kiyo. Acta Urologica Japonica|January 13, 2021
[A Case of Extragonadal Germ Cell Tumor Treated by Induction Therapy with A Reduced Bep Regimen]Shunsuke Owa, Takeshi Sasaki, Mikiya Ishihara, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 7, 2021
[Presurgical Treatment with Axitinib and Pembrolizumab Reduced Operation Risk by Downsizing the Vena Cava Tumor Thrombus in Clear Cell Renal Cell Carcinoma : A Case Report]Sota Inaba, Takeshi Sasaki, Yuna Hattori, et al.
Cancer Medicine|July 22, 2022
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort studyKatsuhiro Ito, Yuki Kita, Akira Yokomizo, et al.
The Prostate|April 4, 2025
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE StudyTakehiko Okamura, Kouji Izumi, Satoshi Kurokawa, et al.
European Urology Open Science|July 11, 2022
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled TrialKouji Izumi, Takashi Shima, Koji Mita, et al.
The Prostate|September 20, 2024
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCaNobumichi Tanaka, Kouji Izumi, Yasushi Nakai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 20, 2026
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCaSeiji Hoshi, Kouji Izumi, Satoru Meguro, et al.
Pageof 4